MedTrace Logo

A Study to Evaluate Safety and Efficacy of YM178 in Patients With Overactive Bladder

NCT00966004 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1139

Last updated 2024-10-31

No results posted yet for this study

Summary

The purpose of the study is to evaluate the effect of YM178 in patients with overactive bladder for 12-week administration.

Conditions

  • Urinary Bladder, Overactive

Interventions

DRUG

YM178

oral

DRUG

Placebo

oral

DRUG

tolterodine

oral

Sponsors & Collaborators

  • Astellas Pharma Inc

    lead INDUSTRY

Principal Investigators

  • Use Central Contact · Astellas Pharma Inc

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-07-24
Primary Completion
2010-02-15
Completion
2010-02-15

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00966004 on ClinicalTrials.gov